We provide you with 20 years of free, institutional-grade data for CRDF stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CRDF. Explore the full financial landscape of CRDF stock.
| Reported Date | CIK | Ticker | Type |
|---|
Cardiff Oncology, Inc(NASDAQ:CRDF) 
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has c...
Website: https://cardiffoncology.com/
Founded: 1999
Full Time Employees: 12
CEO: Mark Erlander
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about CRDF stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.